Home Cart Sign in  
Chemical Structure| 863031-21-4 Chemical Structure| 863031-21-4

Structure of Azilsartan medoxomil
CAS No.: 863031-21-4

Chemical Structure| 863031-21-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Azilsartan Medoxomil is an orally available angiotensin II type 1 (AT1) receptor antagonist with IC50 value of 2.6 nM.

Synonyms: TAK-491

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Azilsartan medoxomil

CAS No. :863031-21-4
Formula : C30H24N4O8
M.W : 568.53
SMILES Code : O=C(C1=C2N(CC3=CC=C(C4=CC=CC=C4C(N5)=NOC5=O)C=C3)C(OCC)=NC2=CC=C1)OCC6=C(C)OC(O6)=O
Synonyms :
TAK-491
MDL No. :MFCD19443688
InChI Key :QJFSABGVXDWMIW-UHFFFAOYSA-N
Pubchem ID :135409642

Safety of Azilsartan medoxomil

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Azilsartan medoxomil

GPCR

Isoform Comparison

Biological Activity

Target
  • AT1 receptor

    AT1 receptor, IC50:2.6 nM

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01715584 Hypertension Phase 4 Recruiting December 31, 2019 Canada, Ontario ... More >> London Health Sciences Centre - Victoria Campus Recruiting London, Ontario, Canada, N6A 5W9 Contact: Craig J Railton, MD, PhD    519 685 8500 ext 58525    Craig.Railton@lhsc.on.ca    Principal Investigator: Craig J Railton, MD, PhD          Sub-Investigator: Jonathan Fairbairn, BSc          Sub-Investigator: George Nicoloau, MD          Sub-Investigator: Robert Gros, PhD          Sub-Investigator: Jason Franklin, MD          Sub-Investigator: John Yoo, MD          Sub-Investigator: Kevin Fung, MD          Sub-Investigator: Anthony Nichols, MD          Sub-Investigator: Danielle McNeil, MD Less <<
NCT02235909 Hypertension Phase 3 Recruiting August 2020 -
NCT00762736 Diabetes Mellitus Phase 2 Completed - -
NCT00376181 Type 2 Diabetes Phase 3 Terminated(Combination formula... More >>tion concerns) Less << - -
NCT02100319 - Completed - Japan ... More >> Osaka, Japan Tokyo, Japan Less <<
NCT01289132 Essential Hypertension Phase 2 Completed - -
NCT01124656 Diabetes Mellitus, Type 2 Phase 3 Terminated(Formulation issues.... More >>) Less << - -
NCT03006796 - Recruiting June 2019 Russian Federation ... More >> City Hospital №5 Recruiting Moscow, Russian Federation, 107015 Contact: Elena Y Shupenina, PhD    +74992684459 Less <<
NCT01985152 Health Phase 1 Unknown - China ... More >> TEDA International Cardiovascular Hospital Recruiting Tianjin, China Contact: Jie Hou, Associate Chief Physician    86-022-65209939       Principal Investigator: Jie Hou, Associate Chief Physician Less <<
NCT01609959 Hypertension Phase 4 Completed - Japan ... More >> First Department of Nara Medical University Kashihara, Nara, Japan, 634-8522 Less <<
NCT00362115 - Completed - -
NCT00759551 Hypertension Phase 2 Completed - -
NCT02079805 Essential Hypertension Complic... More >>ated by Type 2 Diabetes Mellitus Less << Phase 4 Completed - Japan ... More >> Kyoto-Shi, Kyoto, Japan Less <<
NCT02079805 - Completed - -
NCT00847626 Hypertension Phase 3 Completed - -
NCT02181816 - Completed - Japan ... More >> Osaka, Japan Tokyo, Japan Less <<
NCT00362115 Hypertension Phase 2 Completed - -
NCT00847626 - Completed - -
NCT00696436 Hypertension Phase 3 Completed - -
NCT02407210 Essential Hypertension Phase 3 Unknown - China ... More >> Beijing ANZHEN Hospital Recruiting Beijing, China, 100029 Contact: Changsheng Ma, Professor    86-010-64456078    chshma@vip.sina.com    Principal Investigator: Changsheng Ma, Professor Less <<
NCT02786082 Hypertension Phase 1 Completed - -
NCT02609490 Hypertension Phase 3 Completed - China ... More >> Peking University First hospiatl Beijing, China, 100000 Less <<
NCT01762501 - Completed - -
NCT02072330 Grade I or II Essential Hypert... More >>ension Less << Phase 2 Phase 3 Completed - Japan ... More >> Touon-shi, Ehime, Japan Fukuoka-shi, Fukuoka, Japan Hiroshima-shi, Hiroshima, Japan Sapporo-shi, Hokkaido, Japan Hanamaki-shi, Iwate, Japan Morioka-shi, Iwate, Japan Kumamoto-shi, Kumamoto, Japan Kyoto-shi, Kyoto, Japan Sendai-shi, Miyagi, Japan Osaka-shi, Osaka, Japan Suita-shi, Osaka, Japan Shinjuku-ku, Tokyo, Japan Toyama-shi, Toyama, Japan Less <<
NCT01762501 Hypertension Not Applicable Completed - -
NCT02348658 Hypertension Phase 1 Completed - Japan ... More >> Fukuoka-shi, Fukuoka, Japan Less <<
NCT00696241 Hypertension Phase 3 Completed - -
NCT02401464 - Completed - -
NCT02277691 Essential Hypertension Phase 3 Completed - Japan ... More >> Nagoya-shi, Aichi, Japan Chiba-shi, Chiba, Japan Itojima-shi, Fukuoka, Japan Kouriyama-shi, Fukushima, Japan Sapporo-shi, Hokkaido, Japan Amagasaki-shi, Hyougo, Japan Tsukuba-shi, Ibaragi, Japan Morioka-shi, Iwate, Japan Sakaide-shi, Kagawa, Japan Takamatsu-shi, Kagawa, Japan Kawasaki-shi, Kanagawa, Japan Kyoto-shi, Kyoto, Japan Uji-shi, Kyoto, Japan Sendai-shi, Miyagi, Japan Hirakata-shi, Osaka, Japan Osaka-shi, Osaka, Japan Takatsuki-shi, Osaka, Japan Saitama-shi, Saitama, Japan Tokorozawa-shi, Saitama, Japan Yaizu-shi, Shizuoka, Japan Chiyoda-ku, Tokyo, Japan Choufu-shi, Tokyo, Japan Kodaira-shi, Tokyo, Japan Koutou-ku, Tokyo, Japan Setagaya-ku, Tokyo, Japan Shinagawa-ku, Tokyo, Japan Shinjuku-ku, Tokyo, Japan Choufu-shi, Japan Kawasaki-shi, Japan Koutou-ku, Japan Morioka-shi, Japan Sakaide-shi, Japan Setagaya-ku, Japan Shinagawa-ku, Japan Shinjuku-ku, Japan Tsukuba-shi, Japan Uji-shi, Japan Yaizu-shi, Japan Less <<
NCT00696436 - Completed - -
NCT02277691 - Completed - -
NCT02092025 - Completed - Japan ... More >> Osaka, Japan Tokyo, Japan Less <<
NCT02348658 - Completed - -
NCT00696241 - Completed - -
NCT02401464 Japanese Healthy Adult Males Phase 1 Completed - Japan ... More >> Kagoshima, Japan Less <<
NCT00591266 Hypertension Phase 3 Completed - -
NCT00591773 Hypertension Phase 3 Completed - -
NCT00591266 - Completed - -
NCT00591773 - Completed - -
NCT00760214 Hypertension Phase 3 Completed - -
NCT00760214 - Completed - -
NCT00696384 Hypertension Phase 3 Completed - -
NCT01078376 - Terminated(Business Decision (... More >>see below)) Less << - -
NCT00696384 - Completed - -
NCT00591253 Hypertension Phase 3 Completed - -
NCT00846365 Essential Hypertension Phase 3 Completed - -
NCT01078376 Hypertension Phase 1 Terminated(Business Decision (... More >>see below)) Less << - United States, Arkansas ... More >> Little Rock, Arkansas, United States United States, Georgia Atlanta, Georgia, United States United States, Kentucky Louisville, Kentucky, United States United States, Ohio Toledo, Ohio, United States United Kingdom Birmingham, England, United Kingdom Bristol, England, United Kingdom London, England, United Kingdom Manchester, England, United Kingdom Less <<
NCT00591578 Hypertension Phase 3 Completed - -
NCT00591578 - Completed - -
NCT01033071 Essential Hypertension Phase 3 Completed - -
NCT00591253 - Completed - -
NCT00996281 Essential Hypertension Phase 3 Completed - Austria ... More >> Graz, Styria, Austria Germany Karlsruhe, Baden-Wurttemberg, Germany Hannover, Lower Saxony, Germany Kiel-Kronshagen, Schleswig-Holstein, Germany Netherlands Breda, North Brabant, Netherlands Eindhoven, North Brabant, Netherlands Amsterdam, North Holland, Netherlands Velp, Rheden, Netherlands Leiderdorp, South Holland, Netherlands Zoetermeer, South Holland, Netherlands Rotterdam, Zuid-Holland, Netherlands Groningen, Netherlands Poland Bydgoszcz, Kuyavian-Pomeranian, Poland Skierniewice, L0dz, Poland Zgierz, L0dz, Poland Gdansk, Pomeranian, Poland Gdynia, Pomeranian, Poland Sopot, Pomeranian, Poland Mikolow, Silesian, Poland United Kingdom Avon, England, United Kingdom Bolton, England, United Kingdom Chorley, England, United Kingdom Inverness, England, United Kingdom Liverpool, England, United Kingdom Surrey, England, United Kingdom Warwickshire, England, United Kingdom Less <<
NCT01033071 - Completed - -
NCT00846365 - Completed - -
NCT03434977 Healthy Adult Male Participant... More >>s Less << Phase 1 Completed - Japan ... More >> Fukuoka Mirai Hospital Fukuoka, Japan Less <<
NCT00996281 - Completed - -
NCT01309828 - Completed - -
NCT00695955 Hypertension Phase 3 Completed - -
NCT02400775 Essential Hypertension With St... More >>able Angina and Dyslipidemia Less << Phase 4 Withdrawn - Japan ... More >> Tokushima, Japan Less <<
NCT00695955 - Completed - -
NCT01309828 Safety Phase 3 Completed - -
NCT01496430 Hypertension ... More >>Diabetes Less << Phase 3 Terminated(Business Decision; ... More >>No Safety Or Efficacy Concerns. (See below)) Less << - -
NCT01774591 Hypertension Not Applicable Completed - United States, Illinois ... More >> University of Chicago Chicago, Illinois, United States, 60637 Less <<
NCT01774591 - Completed - -
NCT00818883 Essential Hypertension Phase 3 Completed - -
NCT03652792 Bioequivalence of Two Azilsart... More >>an Formulations Less << Phase 1 Completed - Hong Kong ... More >> Phase I Clinical Trial Centre, Chinese University of Hong Kong Hong Kong, Sha Tin New Territories, Hong Kong, 000000 Less <<
NCT00818883 - Completed - -
NCT03042299 Japanese Healthy Adult Male Pa... More >>rticipants Less << Phase 1 Completed - Japan ... More >> Nishi Kumamoto Hospital Kumamoto, Japan Less <<
NCT02791438 Pediatric Hypertension Phase 3 Active, not recruiting June 11, 2019 Japan ... More >> Nagakute, Aichi, Japan Nagoya, Aichi, Japan Obu, Aichi, Japan Sapporo, Hokkaido, Japan Kobe, Hyogo, Japan Kanazawa, Ishikawa, Japan Yokohama, Kanagawa, Japan Nankoku, Kochi, Japan Sendai, Miyagi, Japan Shimajiri-gun, Okinawa, Japan Izumi, Osaka, Japan Osaka Sayama, Osaka, Japan Otsu, Shiga, Japan Shimotsuke, Tochigi, Japan Fuchu, Tokyo, Japan Nerima-ku, Tokyo, Japan Ota-ku, Tokyo, Japan Setagaya-ku, Tokyo, Japan Shinjuku-ku, Tokyo, Japan Akita, Japan Chiba, Japan Fukuoka, Japan Fukushima, Japan Hiroshima, Japan Niigata, Japan Okayama, Japan Osaka, Japan Saitama, Japan Shizuoka, Japan Wakayama, Japan Less <<
NCT02480764 Essential Hypertension Phase 3 Completed - -
NCT01496430 - Terminated(Business Decision; ... More >>No Safety Or Efficacy Concerns. (See below)) Less << - -
NCT02451150 Pediatric Hypertension Phase 3 Completed - Japan ... More >> Fuchu, Japan Oofu, Japan Setagaya-ku, Japan Less <<
NCT03042299 - Completed - -
NCT02451150 - Completed - -
NCT01456169 - Completed - -
NCT02235519 Hypertension ... More >>Obesity Type 2 Diabetes Mellitus Less << Phase 2 Phase 3 Unknown June 2015 Mexico ... More >> Hospital General de Mexico "Dr. Eduardo Liceaga" Recruiting Mexico, Mexico, D.F., Mexico, 06720 Contact: Juan A Peralta, bachelor Less <<
NCT02541669 Healthy Volunteer Phase 1 Completed - China, Beijing,P.R. ... More >> Beijing, Beijing,P.R., China Less <<
NCT02203916 Hypertension Phase 3 Completed - Korea, Republic of ... More >> Chuncheon-Si, Gangwon-do, Korea, Republic of Wonju-Si, Gangwon-do, Korea, Republic of Anyang-si, Gyeonggi-do, Korea, Republic of Goyang-si, Gyeonggi-do, Korea, Republic of Seongnam-si, Gyeonggi-do, Korea, Republic of Suwon-si, Gyeonggi-do, Korea, Republic of Daegu, Gyeongsangbuk-do, Korea, Republic of Yangsan-si, Gyeongsangnam-do, Korea, Republic of Jeonju-si, Jeollabuk-do, Korea, Republic of Gwangju, Jeollanam-do, Korea, Republic of Busan, Korea, Republic of Daegu, Korea, Republic of Daejeon, Korea, Republic of Incheon, Korea, Republic of Seoul, Korea, Republic of Less <<
NCT02517866 Essential Hypertension ... More >> Type 2 Diabetes Mellitus Less << Phase 4 Completed - China, Hong Kong ... More >> Hong Kong, Hong Kong, China Taiwan Changhua county, Taiwan Kaohsiung City, Taiwan Kaohsiung, Taiwan Taichung, Taiwan Tainan City, Taiwan Taipei, Taiwan Taoyuan County, Taiwan Thailand Bangkok, Thailand Chiang Mai, Thailand Khon Kaen, Thailand Pathumtani, Thailand Less <<
NCT01456169 Essential Hypertension Phase 3 Completed - -
NCT02203916 - Completed - -
NCT03539627 - Not yet recruiting June 2021 -
NCT02756819 - Completed - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.76mL

0.35mL

0.18mL

8.79mL

1.76mL

0.88mL

17.59mL

3.52mL

1.76mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories